Medical cannabis use in the UK has evolved significantly since it was first legalised in November 2018. Yet, many patients and healthcare professionals remain uncertain about what exactly “unlicensed specials” means in this context. Understanding this terminology is crucial for anyone considering cannabis-based treatment, particularly since medical cannabis is not widely available as a licensed medicine through the NHS.
In this article, we’ll unpack the unlicensed specials meaning, explain how the MHRA unlicensed specials framework regulates supply, and explore what this means for patients seeking medical cannabis via private specialist clinics. We’ll also clarify eligibility criteria after conventional treatments and the important clinical judgement involved in prescribing these treatments.
What Are “Unlicensed Specials”?
“Unlicensed specials” is a term used within UK medicines regulation to describe medicinal products that do not have a standard marketing authorisation (or licence) issued by the Medicines and Healthcare products Regulatory Agency ( MHRA), but which are lawfully supplied to meet special clinical needs.
Unlike licensed medicines, which have undergone rigorous evaluation for safety, quality, and efficacy, unlicensed specials are prepared or imported to order under a special exemption when no licensed alternative meets a patient’s needs.
This regulatory pathway allows prescribers greater flexibility to provide treatments like medical cannabis which currently have few or no licensed options in the UK market.
Key Features of Unlicensed Specials
- They are not authorised medicines but are legally supplied when licensed alternatives are unavailable. The quality and safety manufacturing standards apply, but no formal MHRA authorisation exists for the final product. Prescribers must take additional responsibility for clinical judgement and risk-benefit analysis when prescribing unlicensed specials. Supply usually requires close collaboration with specialist dispensers or manufacturers who produce these medicines under strict controls.
Why Is Medical Cannabis Considered an Unlicensed Special in the UK?
Currently, very few cannabis-based products have full UK marketing authorisations; one example is Sativex® (a cannabis extract mouth spray licensed for multiple sclerosis spasticity). However, this licensed product covers only very specific indications and formulations.
The majority of other medical cannabis preparations—such as oils, sprays, or capsules used to treat epilepsy, chronic pain, or chemotherapy-induced nausea—fall into the category of unlicensed specials. This means:
- There is no broad licence allowing them to be prescribed on the NHS for most indications. Patients must obtain these medicines privately or under very limited NHS exceptions. Doctors prescribing these products must usually be specialists registered on a dedicated prescribing register.
MHRA’s Role in Regulating Unlicensed Specials
The MHRA oversees all medicines regulation in the UK, including unlicensed specials. While unlicensed specials are exempt from the full licensing process, companies producing these products must comply with manufacturing standards and notify the MHRA of their activity.
For medical cannabis, the MHRA sets out guidelines to ensure that cannabis products supplied as unlicensed specials meet quality and safety standards, even though they lack formal licences. This approach is often called the regulated supply cannabis UK pathway.
Who Is Eligible to Access Medical Cannabis as an Unlicensed Special?
Because of the limited evidence base and regulatory status, access to medical cannabis under the unlicensed specials framework is carefully managed. The general eligibility pathway typically requires that:
A patient has exhausted conventional licensed treatment options that are appropriate for their condition. Specialist medical assessment confirms that the patient’s symptoms are severe or refractory enough to justify use of cannabis-based medicine. The prescribing clinician deems the risk-benefit balance favourable for that individual patient. There is informed consent after a detailed discussion of potential benefits, risks, and uncertainties.Because of these factors, medical cannabis prescribed as an unlicensed special is usually reserved for complex patients under specialist care, such as neurologists for epilepsy or pain specialists for neuropathic pain.
What About NHS Access?
While medical cannabis was legalised in 2018 on prescription, NHS access remains very limited. The majority of prescribing is via private clinics, often requiring patients to self-fund specialist consultations and the medications themselves.
Some pioneering NHS centres are beginning to offer cannabis medicines to select patients, but this remains rare and highly regulated.
Specialist Consultation and Prescribing Register
In the UK, only doctors on a designated specialist prescribing register maintained by national bodies can prescribe medical cannabis as an unlicensed special.
This is because of the need for expert knowledge to:
- Assess complex clinical indications on a case-by-case basis. Apply current evidence and guidelines to maximise benefits. Understand dosing, product types, and potential side effects. Monitor patients closely for efficacy and adverse reactions.
Many patients seeking medical cannabis privately therefore require a referral or direct appointment with specialists in private clinics that offer this service. The process involves thorough assessment, laboratory testing if needed, and comprehensive dotimes.co.uk follow-up.
Risk-Benefit Clinical Judgement
Prescribing an unlicensed special such as medical cannabis demands careful risk-benefit clinical judgement. This is because:
- Robust large-scale clinical trials are still emerging for many cannabis indications. Long-term safety data remain limited. Interactions with other medications must be considered. Individual patient factors vary widely.
Doctors weigh symptomatic relief, quality of life improvement, and potential reduction in use of opioids or other harmful drugs against the risks of adverse effects, dependency, psychiatric symptoms, and unknown long-term outcomes.
Due to these complexities, prescribing medical cannabis as an unlicensed special is often a last resort after well-documented conventional treatments have failed.
Cost Example: Understanding the Financial Aspect of Unlicensed Medical Cannabis
Accessing medical cannabis as an unlicensed special can be costly due to the private nature of most services and the bespoke manufacturing of these products. To illustrate, here is a typical price breakdown for a monthly supply:
Item Description Typical Cost (GBP) Private Specialist Consultation Initial assessment and prescribing appointment £250 - £350 Medical Cannabis Oil Supply One month’s supply of cannabis oil as unlicensed special £350 - £700 Follow-up Consultation Monitoring and dose adjustment (optional) £150 - £200 Total Approximate Cost (First Month) £600 - £1050These costs can vary significantly depending on the clinic, product strength, and treatment duration. Importantly, NHS-funded access is rarely available outside clinical trials or exceptional cases.
Summary: What You Need to Know About Medical Cannabis as an Unlicensed Special
- Unlicensed specials meaning: medicines legally supplied without formal MHRA marketing authorisation under a special clinical need exemption. MHRA unlicensed specials: regulated framework ensures quality and safety controls, though products aren’t fully licensed. Regulated supply cannabis UK: medical cannabis products as unlicensed specials must meet manufacturing and safety standards within this system. Access requires specialist assessment after other licensed treatments have been tried and found ineffective or unsuitable. Prescribing is restricted to doctors on specialist registers who apply detailed risk-benefit clinical judgement. Private specialist consultations and the drug supply can be costly, with limited NHS availability.
Sharing This Information
If you found this guide helpful, please share it on your favourite social platform so more patients can understand the realities of medical cannabis prescribing in the UK:
- Facebook Twitter LinkedIn Tumblr Pinterest Pocket Skype Messenger Reddit WhatsApp Telegram VKontakte Odnoklassniki
For personalised advice, always consult a specialist clinic or healthcare professional experienced in medical cannabis management.